Narrow-band UVB therapy is best known as a treatment for skin conditions such as psoriasis and vitiligo, but the same underlying principle, using a specific band of ultraviolet light to influence immune activity in tissue, has found application beyond dermatology. In otolaryngology, narrow-band UVB and related light wavelengths are used in intranasal phototherapy for allergic rhinitis, illustrating how a single technology can be adapted to different mucosal surfaces of the body.
What Makes UVB Light "Narrow-Band"?
Ultraviolet B light covers a range of wavelengths, and narrow-band UVB refers to a restricted portion of that spectrum, most commonly centered around 311 to 313 nanometers, that has been identified as effective for modulating immune cell activity while minimizing wavelengths associated with greater skin damage. This selectivity is what distinguishes narrow-band UVB from older broad-band UVB therapy, which covered a wider and less targeted range of wavelengths.
How Does UVB Affect Immune Cells?
The uvb mechanism of action centers on immunomodulation, meaning the light influences the behavior of immune cells rather than simply killing tissue. When narrow-band UVB reaches the skin or mucosal surface, it is commonly reported to reduce the activity and number of certain T-lymphocytes involved in inflammatory skin and mucosal conditions, and to influence mast cells and eosinophils, cells heavily involved in allergic reactions. By limiting the release of histamine and other inflammatory mediators from these cells, UVB-based phototherapy can reduce the intensity of inflammatory symptoms without relying on systemic medication.
From Dermatology to the Nasal Passage
The dermatological use of narrow-band UVB for conditions like psoriasis, eczema, and vitiligo is well established in clinical practice. Applying a similar principle to the nasal mucosa is a more recent area of interest, particularly for allergic rhinitis, a condition driven by an exaggerated immune response to allergens such as pollen or dust mites. Because the nasal lining contains many of the same mast cells, eosinophils, and T-lymphocytes implicated in skin allergic conditions, researchers and manufacturers have explored intranasal phototherapy that combines narrow-band UVB with visible and infrared wavelengths as a non-pharmacological option for allergy symptom management.
An Example of Intranasal Phototherapy Technology
INVAMED manufactures the Voltran Phototherapy System, an intranasal phototherapy device intended for allergic rhinitis that combines narrow-band UVB, visible light, and infrared wavelengths. As described by the manufacturer, sessions are brief, typically around five minutes, and are designed to be non-pharmacological, without an associated heat sensation during treatment. The manufacturer states that the device's light wavelengths act on mast cells, T-lymphocytes, and eosinophils in the nasal mucosa to help limit histamine release, consistent with the broader immunomodulation mechanism described for narrow-band UVB elsewhere in medicine. More detail is available on the INVAMED product page for the Voltran Phototherapy System. Availability and indications vary by country, and clinicians should refer to the Instructions for Use for complete information.
Why Does the Application Matter for Treatment Planning?
Although the underlying uvb mechanism is similar across applications, dosing, exposure duration, and treatment schedules differ meaningfully between skin and mucosal phototherapy because tissue thickness, sensitivity, and the surrounding physiology are not the same. A qualified physician determines whether narrow-band UVB-based treatment, in any application, is appropriate for an individual patient, taking into account the specific condition, its severity, and the patient's overall health.
Can UVB-based nasal therapy replace allergy medication?
Intranasal phototherapy is generally considered a non-pharmacological option that may be used alongside or as an alternative to certain allergy treatments, depending on the patient. It is not framed as guaranteed to eliminate allergic rhinitis symptoms, and a physician determines how it fits into an individual's overall management plan.
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.